Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, Shu CJ, Sathyanarayanan S, Zuerndorfer S, Simpson T, Gostissa M, Briskin M, Law D, Michaelson J, Harvey CJ. Hanson A, et al. Among authors: law d. PLoS One. 2020 Sep 24;15(9):e0239595. doi: 10.1371/journal.pone.0239595. eCollection 2020. PLoS One. 2020. PMID: 32970735 Free PMC article.
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA. Afar DE, et al. Among authors: law da. Mol Cancer Ther. 2004 Aug;3(8):921-32. Mol Cancer Ther. 2004. PMID: 15299075
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V. Bhaskar V, et al. Among authors: law da. Cancer Res. 2003 Oct 1;63(19):6387-94. Cancer Res. 2003. PMID: 14559828
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J, Hevezi P, Cass KM, Watson S, Evangelista F, Powers RA, Finck B, Wills M, Caras I, Fang Y, McDonald D, Johnson D, Murray R, Jeffry U. Ramakrishnan V, et al. Among authors: law da. J Exp Ther Oncol. 2006;5(4):273-86. J Exp Ther Oncol. 2006. PMID: 17024968
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. Tai YT, et al. Among authors: law d. Blood. 2008 Aug 15;112(4):1329-37. doi: 10.1182/blood-2007-08-107292. Epub 2007 Sep 28. Blood. 2008. PMID: 17906076 Free PMC article.
Chemical and linguistic considerations for encoding Chinese characters: an embodiment using chain-end degradable sequence-defined oligourethanes created by consecutive solid phase click chemistry.
Zhang L, Krause TB, Deol H, Pandey B, Xiao Q, Park HM, Iverson BL, Law D, Anslyn EV. Zhang L, et al. Among authors: law d. Chem Sci. 2024 Mar 11;15(14):5284-5293. doi: 10.1039/d3sc06189b. eCollection 2024 Apr 3. Chem Sci. 2024. PMID: 38577351 Free PMC article.
496 results